Time on therapy and concomitant medication use of mepolizumab in Canada: a retrospective cohort study.
Jason K LeeAlain GendronMichelle KnutsonNiroshan SriskandarajahStefan D BaralStephen G NoorduynPublished in: ERJ open research (2021)
About half of the patients who initiate therapy with mepolizumab discontinue treatment within the first or second year. Concomitant use of short-acting β2-agonists and oral corticosteroids drops during mepolizumab use. https://bit.ly/3aRISqS.